Immune checkpoint inhibitor-associated hepatitis and colitis: current understanding and clinical approaches
Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment by harnessing the immune system to target tumors. The introduction of ipilimumab, an anti-CTLA-4 monoclonal antibody, marked a major milestone in immuno-oncology when it was approved by the U.S. Food and Drug Administration (FD...
Guardat en:
| Autors principals: | , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Taylor & Francis Group
2026-07-01
|
| Col·lecció: | Immunological Medicine |
| Matèries: | |
| Accés en línia: | https://www.tandfonline.com/doi/10.1080/25785826.2026.2679874 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|